Pomerantz Law Firm Files Class Action Against Savara Inc. Over Alleged Securities Violations

Class Action Lawsuit Filed Against Savara Inc.

Pomerantz LLP recently announced the filing of a class action lawsuit targeting Savara Inc., a clinical-stage biopharmaceutical firm focused on treating rare respiratory diseases. The lawsuit, registered under docket number 25-cv-05147 at the United States District Court for the Eastern District of Pennsylvania, includes a class of all individuals and entities, except the defendants, who purchased or acquired Savara securities from March 7, 2024, to May 23, 2025, collectively referred to as the “Class Period.” This legal action seeks to recover damages stemming from purported violations of federal securities laws by the company and certain senior officials.

The Allegations

Investors have until November 7, 2025, to request the Court appoint them as Lead Plaintiff for this class. Individuals interested in the case can find more details or obtain a copy of the Complaint through Pomerantz Law Firm’s website. According to the firm, the lawsuit stems from claims that Savara misrepresented key aspects of its business and financial stability. Particularly, the lawsuit highlights that Savara’s lead product candidate, MOLBREEVI, was being touted inaccurately to investors due to potential obstacles in its regulatory approval process from the U.S. Food and Drug Administration (FDA).

Savara, known for its product candidate MOLBREEVI (also called